SIM

BIOLOGICAL3 trials

Sponsors

Gilead Sciences

Conditions

Liver Fibrosis Due to NASHNon-Alcoholic Steatohepatitis (NASH)

Phase 2

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

TerminatedNCT01672866

Gilead SciencesLiver Fibrosis Due to NASH

Start: 2012-12-05End: 2016-12-29Updated: 2019-03-27

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

TerminatedNCT01672879

Gilead SciencesLiver Fibrosis Due to NASH

Start: 2012-10-29End: 2017-01-03Updated: 2019-03-27

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

CompletedNCT02466516

Gilead SciencesNon-Alcoholic Steatohepatitis (NASH)

Start: 2015-06-08End: 2016-10-11Updated: 2019-06-26

Related Papers

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.

2024-08-0728 citations

A computational analysis of the binding free energies of apoptosis signal-regulating kinase 1 inhibitors from different chemotypes

Molecular Simulation2021-05-123 citations

The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

2020-12-0881 citations

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

2018-07-07278 citations

An update on the pharmacological treatment of nonalcoholic fatty liver disease: Beyond lifestyle modifications

Clinical Liver Disease2018-04-0139 citations